NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
13 trialsNCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT02860039 2024-10-22
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT05116917 2024-05-28
INFLUENCE
Herlev Hospital
Phase 2 Terminated
NCT05909423 2023-06-18
FLU-IMMUNE
Zealand University Hospital
Phase 2 Not yet recruiting
NCT05322330 2023-02-09
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04591379 2022-12-13
Intratumoral Influenza Vaccine for Early Colorectal Cancer
Zealand University Hospital
Phase 2 Completed
NCT02566265 2019-01-30
SHIVERING 2
Yale University
Phase 2 Completed
NCT01924169 2018-09-20
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01135329 2018-07-03
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00596336 2017-04-12
CLLIFVAC
The Royal Bournemouth Hospital
Phase 2 Terminated
NCT01205581 2016-09-23
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01666782 2016-06-24
IMMUNE
Rochester General Hospital
Phase 2 Completed